Ovid Therapeutics Inc.
OVID
$2.70
-$0.05-1.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.37% | 3.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.61% | 37.16% | |||
| Operating Income | 13.72% | -45.17% | |||
| Income Before Tax | 11.65% | -275.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.65% | -275.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.65% | -275.80% | |||
| EBIT | 13.72% | -45.17% | |||
| EBITDA | 13.64% | -45.09% | |||
| EPS Basic | 39.10% | -202.63% | |||
| Normalized Basic EPS | 40.26% | 10.55% | |||
| EPS Diluted | 39.10% | -202.63% | |||
| Normalized Diluted EPS | 40.26% | 10.55% | |||
| Average Basic Shares Outstanding | 45.00% | 66.73% | |||
| Average Diluted Shares Outstanding | 45.00% | 66.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||